Meeting
2013 Genitourinary Cancers Symposium
Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP).
Authors
Sergio Bracarda
Department of Oncology, USL-8, Ospedale San Donato, Arezzo, Italy
Sergio Bracarda , Paolo Marchetti , Donatello Gasparro , Angela Gernone , Francesco Boccardo , Caterina Messina , Luca Gianni , Roberto Bortolus , Lucia Fratino , Giuseppe Fornarini , Giacomo Carteni , Marcello Tucci , Roberto Mazzanti , Tiziana Scotto , Andrea Martoni , Umberto Basso , Giuseppe Procopio , Franco Morelli , Rodolfo Mattioli , Giuseppe Di Lorenzo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01254279
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 189)
DOI
10.1200/jco.2013.31.6_suppl.189
Abstract #
189
Poster Bd #
B13
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
First Author: Zafar Malik
Poster
2013 ASCO Annual Meeting
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
Poster
2013 Genitourinary Cancers Symposium
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).
First Author: Amit Bahl
Poster
2012 ASCO Annual Meeting
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger